FDA Approves Leucovorin for Autism Treatment Amid Expert Concerns
The FDA has approved leucovorin for treating speech-related deficits in autism, prompting debate among medical experts regarding its efficacy and the need for further research.
The U.S. Food and Drug Administration (FDA) has approved leucovorin, a derivative of vitamin B, for treating speech-related deficits in children with autism spectrum disorder (ASD). This decision has surprised many in the medical community, including Dr. Richard Frye, a child neurologist who had been discussing the development of a customized version of the drug with federal regulators. Dr. Frye expressed his astonishment, stating, "So we were kinda surprised that they were just approving it right out of the gate without more studies or anything."
The FDA's approval is based on studies suggesting that some children with autism have low levels of folate in the brain, which leucovorin can potentially address. However, leading autism researchers and organizations have distanced themselves from this decision, citing the limited scope and size of existing studies. Dr. David Mandell, a psychiatrist at the University of Pennsylvania, commented, "We have nothing resembling even moderate evidence that leucovorin is an effective treatment for autism symptoms."
Despite the FDA's approval, experts emphasize the need for further research to confirm leucovorin's efficacy and safety in treating autism-related symptoms. They advise that any use of the drug should be conducted under strict medical supervision and within the framework of controlled clinical trials.